E-submission
Search
- Page Path
- HOME > Search
Newsletter
- What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
- Kristen Muller, Julie M. Jorns, Gary Tozbikian
- J Pathol Transl Med. 2022;56(3):170-171. Published online May 15, 2022
- DOI: https://doi.org/10.4132/jptm.2022.04.25
- 5,208 View
- 441 Download
- 2 Citations
-
Abstract
PDF - The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.
-
Citations
Citations to this article as recorded by
- Immune checkpoint inhibitor resistance in hepatocellular carcinoma
Zhijie Wang, Yichuan Wang, Peng Gao, Jin Ding
Cancer Letters.2023; 555: 216038. CrossRef - Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
Izzet Dogan, Sercan Aksoy, Burcu Cakar, Gul Basaran, Ozlem Ercelep, Nil Molinas Mandel, Taner Korkmaz, Erhan Gokmen, Cem Sener, Adnan Aydiner, Pinar Saip, Yesim Eralp
Cancers.2023; 15(6): 1667. CrossRef
- Immune checkpoint inhibitor resistance in hepatocellular carcinoma
First
Prev
